Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network

Conclusion: This study confirms that 177Lu-DOTATATE PRRT does not lead to morphologic response on MMs (ORR < 5%). However, it allows MM stability, with few MM-related side effects, and has a relevant impact on MM-related symptoms.

Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Al Mansour, L., De Mestier, L., Haissaguerre, M., Afchain, P., Hadoux, J., Lecomte, T., Morland, D., Cottereau, A. S., De Rycke, O., Tlili, G., Tordo, J., Janier, M., Deville, A., Walter, T. Tags: Clinical Investigations Source Type: research